200 results about "Hypoglycemic Effects" patented technology

The invention provides application of polygonatum cyrtonema polysaccharide in preparation of medicines for treating ulcerative colitis or reducing blood glucose. A main chain of a sugar chain structure of the homogeneous polysaccharide PCP2 in polygonatum cyrtonema is mainly composed of-> 1)-beta-D-Fur-(2->,-> 1, 6)-beta-D-Fur-(2-> and-> 6)-alpha-D-Glcp-(1-> and beta-D-Fur-(2->), a side chain is mainly composed of beta-D-Fur-(2-> and-> 2)-beta-D-Fur-(6-> at a C-6 position of-> 1, 6)-beta-D-Fur-(2->), Fur represents furanose, Glcp represents glucopyranose, Glcp represents glucopyranose, and Glcp represents glucopyranose. The novel polysaccharide compound can relieve intestinal injury of mice, increase expression of tight nectin and mucoprotein, relieve oxidative stress reaction, promote production of short-chain fatty acid and improve composition of intestinal flora, and can be applied to the field of medicine as a medicine for treating ulcerative colitis. Meanwhile, the homogeneous polysaccharide PCP2 in polygonatum cyrtonema can significantly inhibit the activity of alpha-amylase and alpha-glucosidase, can also promote the ability of insulin resistance 3T3-L1 fat cells to uptake and consume glucose, shows a significant hypoglycemic effect, and has a good development prospect in the aspect of preparation of hypoglycemic drugs.

The invention relates to a bifidobacterium animalis subsp. Lactis YYSJ001 with a blood sugar reducing effect and application of the bifidobacterium animalis subsp. Lactis YYSJ001. The classification name of the strain is bifidobacterium animalis subsp. Lactis, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.33471. The invention further relates to a preparation method of the bifidobacterium animalis subsp. Lactis YYSJ001. The bacterial strain has good artificial gastric juice resistance, artificial intestinal juice resistance and intestinal tract adhesion ability, has an inhibition effect on numerous pathogenic bacteria such as escherichia coli, staphylococcus aureus, salmonella, klebsiella pneumoniae and quail chicken enterococcus, and can stimulate intestinal cells to generate glucagon-like peptide-1, so that the bacterial strain can be applied to preparation of various pathogenic bacteria. Diseases of diabetic mice can be effectively improved, and the compound can be used for preparing products for preventing and treating diabetes or assisting in reducing blood sugar.

The invention discloses a hexapeptide with a hypoglycemic effect as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The amino acid sequence of the hexapeptide is Ile-Trp-Asp-Pro-His-Phe, and the amino acid sequence of the hexapeptide is as shown in the specification. The novel hexapeptide IWDPHF with prominent DPP-IV inhibition ability is successfully identified from mulberry leaf proteolysis products through liquid chromatography-mass spectrometry and a virtual screening method, the hexapeptide IWDPHF shows the blood glucose reducing effect superior to that of part of known peptides in an in-vitro enzyme activity inhibition experiment and a zebra fish hyperglycemia model, and no obvious side effect exists; the compound has a good potential of being developed into a hypoglycemic functional product or a drug lead compound. The invention further provides the mulberry leaf peptide with the peptide fragment IWDPHF, and the mulberry leaf peptide can be applied to preparation of drugs or food for reducing blood sugar. The invention provides a new scheme and theoretical basis for treatment of diabetes, and has good market prospect and application potential.

The invention belongs to the technical field of plant active peptides, and particularly relates to a red kidney bean hypoglycemic active peptide and application thereof. The amino acid sequences of the hypoglycemic active peptide are FFGGPAF, SAKPFFSGL and PPGHPFVTF. The invention further discloses a preparation method of the hypoglycemic active peptide. FF, SL and PF for short. The polypeptide is prepared through enzymolysis of red kidney bean protein, and the polypeptide is identified by utilizing ultrafiltration separation and LC-MS / MS (Liquid Chromatography-Mass Spectrometry / Mass Spectrometry); the hypoglycemic active peptides which are high in hypoglycemic effect, free of toxicity, carcinogenicity and sensitization and capable of being absorbed by human intestinal tracts are screened out through a bioinformatics method and molecular docking, then the screened hypoglycemic active peptides and alpha-glucosidase are subjected to molecular docking, and finally three hypoglycemic active peptides FF, SL and PF are screened out. The invention finds that the hypoglycemic active peptides FF, SL and PF have high inhibitory activity on alpha-glucosidase, can obviously promote glucose consumption of insulin resistance model cells, and can be used for preparing hypoglycemic drugs, food and health care products.

The invention provides a fat-reducing composition based on an agaricus bisporus extract as well as a preparation method and application of the fat-reducing composition, and belongs to the technical field of nutrition and health care. The fat-reducing composition comprises the following raw materials in parts by weight: 10-30 parts of an agaricus bisporus extract, 5-15 parts of a green tea extract, 5-15 parts of bitter gourd peptide, 3-10 parts of seaweed meal and 10-30 parts of resistant dextrin. The agaricus bisporus extract disclosed by the invention can regulate intestinal flora and promote fat metabolism; tea polyphenol in the green tea extract can inhibit fat synthesis and promote fat oxidation; momordica charantia peptide has an obvious hypoglycemic effect; the seaweed meal (containing fucoxanthin) has the effects of burning fat cells and eliminating fat accumulation; the resistant dextrin is used as dietary fiber, so that satiety is increased, and caloric intake is reduced. The raw materials cooperate with each other, so that the composition has better fat-reducing and weight-reducing effects, and the total cholesterol and triglyceride levels are reduced.

The invention discloses a photocuring microneedle with ginseng exosome loaded berberine, a preparation method of the photocuring microneedle and application of the photocuring microneedle to tissue repair. A ginseng exosome loaded berberine compound is prepared through a microfluidic technology; filling a needle cavity of a microneedle mold with a needle tip layer preparation solution containing the compound, methylacryloylated hyaluronic acid and methylacryloylated gelatin through a centrifugal method; covering a backing layer preparation solution composed of hyaluronic acid and povidone K90, and centrifuging again; and finally, carrying out light curing, drying and demolding. The prepared composite microneedle is complete and sharp in needle shape and high in forming rate; the efficient entrapment of the active medicine is realized; the biocompatibility is good, and the irritation is low; a cross-linked network structure formed by photocuring is beneficial to realizing controlled release of drugs, the targeted repair function of the ginseng exosome is combined with the hypoglycemic effect of berberine, and a new strategy and technical approach with a prospect are provided for painless, efficient and long-acting treatment of diabetes mellitus.

The invention provides a rehmannia fermented extract, a composition as well as a preparation method and application of the rehmannia fermented extract and the composition, and belongs to the technical field of biological medicines. According to the invention, raw dark green tea and rehmannia are fermented by using a single strain of eurotium cristatum to respectively obtain a raw dark green tea fermentation extract and a rehmannia fermentation extract. Experiments prove that the two extracts have a relatively good inhibition effect on dipeptidyl peptidase-4 when being independently used; furthermore, the two extracts are combined, and animal experiments prove that the composition has relatively good inhibitory activity on intestinal tract and excrement dipeptidyl peptidase-4 and also has a hypoglycemic effect.

The invention provides a healthy food, in particular to a hypoglycemic composition based on homology of medicine and food and gradient fermentation type prebiotics, which is a dry powder preparation and comprises a component A and a component B, the component A is a medicinal and edible component, and the component B is a prebiotic component; the component A is prepared from the following components in parts by mass: 2 to 15 parts of folium mori extract, 2 to 10 parts of bitter gourd extract, 2 to 20 parts of rhizoma dioscoreae extract, 1 to 10 parts of radix puerariae extract, 2 to 10 parts of fructus lycii extract, 0.5 to 5 parts of radix polygonati officinalis extract and 0.5 to 5 parts of rhizoma polygonati extract; the component B is prepared from 20 to 50 parts of resistant dextrin, 5 to 15 parts of xylooligosaccharide, 3 to 10 parts of inulin and 35 to 50 parts of D-psicose. The hypoglycemic activity of the traditional medicinal and edible materials is organically combined with the gradient fermentation type prebiotics, so that the hypoglycemic effect is realized by synergism of multiple action mechanisms, and the problems of single hypoglycemic mechanism and non-ideal blood sugar regulation effect of the existing product are solved.

The invention discloses a marine-derived bioactive peptide with a blood sugar reducing effect, a preparation and application, and belongs to the technical field of bioactive peptides. The amino acid sequence of the bioactive peptide is at least one of FYP, FPF and YAPFPK. Three bioactive peptides with the blood sugar reducing effect are separated and purified from oysters through enzymolysis, ultrafiltration, gel chromatography, liquid chromatography-mass spectrometry and bioinformatics technologies. According to the present invention, chemical synthesis is performed according to the identified peptide fragment sequence, the hypoglycemic activity of the synthesized single peptide fragment and the compounded peptide fragment is detected, and the bioactive peptides have good alpha-glucosidase inhibition activity, such that the bioactive peptides have good application prospects in the preparation of the products with the hypoglycemic effect, and can be widely used in the preparation of the products with the hypoglycemic effect. And a foundation is laid for high value-added utilization of oysters and promotion of research, development and application of functional active peptides.

The invention discloses lactobacillus mucus with a hypoglycemic effect and an application of the lactobacillus mucus in a fermented tea beverage, the lactobacillus mucus is preserved in China Center for Type Culture Collection on December 3, 2024, and the preservation number is CCTCC NO: M20242692. The lactobacillus mucilaginosus disclosed by the invention not only has a remarkable hypoglycemic effect, but also shows a good hypoglycemic effect in a product obtained by co-fermenting the lactobacillus mucilaginosus and the Kangpu tea. The innovative combination not only enriches the nutritional value of the Kangpu tea, but also significantly improves the health benefits of the Kangpu tea, so that the Kangpu tea becomes a preferred beverage for diabetics and people pursuing healthy life, and opens up a new possibility for the functional beverage market.

The technical scheme of the invention discloses black fungus protein capable of reducing blood glucose and resisting oxidation as well as a preparation method and application of the black fungus protein. The amino acid sequence of the black fungus protein is as shown in SEQ ID NO. 1. The protein which is separated and identified from the black fungus for the first time and has the effects of reducing blood glucose and resisting oxidation achieves the effect of reducing blood glucose through double inhibition of alpha-amylase and alpha-glucosidase, meanwhile, the protein has remarkable antioxidant activity, animal experiments prove that fasting blood glucose and body weight of a type II diabetes model mouse can be effectively reduced, and the protein has a good application prospect. The compound has high biological activity and safety, and can be used for developing functional products with hypoglycemic and antioxidant activity.

The invention discloses a cane molasses extract with a blood sugar reducing effect as well as a preparation method and application thereof, and belongs to the field of functional foods. According to the invention, cane molasses is subjected to dissolution, centrifugation, ultrafiltration impurity removal, desalination and nanofiltration concentration, and is mixed with calcium chloride, so that the cane molasses extract with the effect of reducing blood sugar is prepared. Experimental results prove that the cane molasses extract prepared by the invention has the characteristics of low glycemic index (GI), carbohydrate digestive enzyme inhibition, high temperature resistance, long-term storage resistance and the like, can also effectively repair pancreas and liver injury and regulate intestinal flora, and has a comprehensive hypoglycemic effect. The food with low glycemic index is prepared on the basis of the high sucrose carrier for the first time, and the food has sweet taste and the function of reducing blood sugar. The invention provides a new raw material scheme for the preparation of dietary supplement food and hypoglycemic drugs for hyperglycemia people, and has prominent practical application value and wide application prospect.

This invention belongs to the field of intestinal microbiome technology, specifically relating to a capsular polysaccharide derived from Bacteroides salorlis CSP6, its preparation method, and its applications. The monosaccharide composition of the capsular polysaccharide is mainly composed of fucose, glucose, and glucosamine, with a molecular weight of 7.139 × 10⁻⁶. 5 The strain described is deposited at the China Center for Type Culture Collection (CCTCC), accession number CCTCC NO: M20221993. In vitro studies have found that the capsular polysaccharide derived from Bacteroides Salieris CSP6 can inhibit α-glucosidase; in vivo animal experiments have demonstrated that this capsular polysaccharide can inhibit the rise in postprandial blood glucose and has a hypoglycemic effect.

The invention relates to a sugar-free lung-moistening composition for treating diabetes mellitus yin deficiency and dry cough as well as application and a preparation method of the sugar-free lung-moistening composition, aiming at solving the problem that the existing cough-relieving traditional Chinese medicine products are generally not suitable for diabetics to use, and the sugar-free lung-moistening traditional Chinese medicine composition for treating diabetes mellitus yin deficiency and dry cough is prepared from the following raw materials in parts by weight. Comprising 30-40 parts of pears, 15-20 parts of radix polygonati officinalis, 10-15 parts of radix adenophorae, 10-15 parts of radix ophiopogonis, 5-10 parts of Chinese yam, 5-8 parts of fructus momordicae and 3-5 parts of fructus lycii. The sugar-free lung-moistening composition for diabetic yin deficiency and dry cough breaks through the limitation of single effect of a traditional medicine and food homology formula, and has the effects of relieving cough, eliminating phlegm, moistening lung, nourishing yin and assisting in reducing blood sugar.

To provide an adjuvant that can maintain the therapeutic effect while reducing the dose of the SU drugs since sulfonylurea drugs (hereinafter also referred to as "SU drugs"'), which are antidiabetic drugs, induce pancreatic β cell exhaustion when used long-term in addition to the side effects of hypoglycemia and weight gain and have side effects of reduced efficacy (hypoglycemic effect) and renal damage.SOLUTION: If D-allulose is administered before or simultaneously with SU drug administration, the hypoglycemic effect of SU drugs will be enhanced. As a result, the above-mentioned problem is solved because the dose of SU drugs can be significantly reduced. Furthermore, since D-allulose has been eaten by humans, it can provide a highly safe drug when combined with SU drugs.SELECTED DRAWING: Figure 3

The invention belongs to the technical field of medicinal chemistry, and relates to 3-amino-4-(2, 4, 5-trifluorophenyl) bornyl butyrate as well as a preparation method and application thereof. The 3-amino-4-(2, 4, 5-trifluorophenyl) bornyl butyrate has the following structure: the 3-amino-4-(2, 4, 5-trifluorophenyl) bornyl butyrate provided by the invention has an excellent hypoglycemic effect, has a low toxic effect on AC16 cells, and provides a treatment choice with better efficiency and higher safety for diabetics.

The application discloses a benzothiophenone derivative, a preparation method and application thereof. The benzothiophenone derivative, a tautomer, an optical isomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof, and the chemical structure of the benzothiophenone derivative is shown as formula (I), wherein R is any one of the following groups: a substituted alkane and N-benzyl-2-chloroformamide. The benzothiophenone derivative can regulate a PPARγ target as an anti-type 2 diabetes drug, can reserve insulin sensitivity, can avoid related side effects caused by a PPARγ full agonist, and has a 'highly efficient and safe' hypoglycemic effect.

The invention provides vinasse dietary fiber with blood fat reducing activity and a preparation method of the vinasse dietary fiber. The vinasse dietary fiber with relatively high purity is obtained by performing alkali soaking, sodium chlorite bleaching, crushing and drying on the vinasse. The prepared vinasse dietary fiber can effectively improve hyperlipidemia of obese diabetes model mice, reduce triglyceride and total cholesterol levels of serum and liver and improve liver injury, and can be applied to preparation of functional food, health care products, medicines and feeds with the blood glucose reducing effect.

According to the salivation promoting beverage for treating diabetes and the preparation method and chemical and pharmacokinetic application of the salivation promoting beverage, eight medicinal and edible medicinal materials such as folium mori and radix rehmanniae are scientifically matched, and a material basis is laid for the blood glucose reducing effect of a compound through the design of a multi-component and multi-target synergistic effect. The absorption, distribution, metabolism and excretion processes of active ingredients in traditional Chinese medicinal materials in a living body can be systematically illuminated through pharmacokinetic research, meanwhile, strict methodology verification is carried out, a UHPLC-Q-TOF-MS high-resolution mass spectrometry technology and a modern pharmacokinetic application method are creatively integrated, and a set of systematic traditional Chinese medicine compound application strategy is constructed. Not only is the hypoglycemic action mechanism of the compound clarified, but also an innovative technical path and a reliable application normal form are provided for modern application of the traditional Chinese medicine compound, and organic combination of chemical characterization and efficacy evaluation is realized.

The present invention discloses a polyporus badius polysaccharide and its preparation method and application, belonging to the technical field of polysaccharide extraction. The polyporus badius polysaccharide (PPP-0A) includes galactose, fucose, glucose, mannose and xylose, and the molar ratios are 62.26%, 16.96%, 15.23%, 4.68% and 0.87% respectively. The present invention uses techniques such as methylation, scanning electron microscopy, thermogravimetric analysis, nuclear magnetic resonance and atomic force microscopy to determine the structural characteristics of PPP-0A, analyze its composition and properties, and its inhibitory effects on the activities of α-glucosidase and α-amylase. In addition, an in vitro HepG2 cell model induced by high blood glucose and high insulin levels was used to study the hypoglycemic effect of PPP-0A. The present invention provides a theoretical basis for clarifying the relationship between the hypoglycemic activity of PPP-0A and its hypoglycemic effect on type 2 diabetic mice.

The invention relates to application of lactobacillus acidophilus LA85 in preparation of a product with a blood sugar reducing effect. The brand new application of the lactobacillus acidophilus LA85 strain is developed, namely the lactobacillus acidophilus LA85 strain is used for inhibiting alpha-glucosidase, reducing blood sugar and improving diabetes mellitus, and tests prove that the food intake, the water intake and the urine volume of a mouse with type II diabetes mellitus can be effectively controlled after intervention of the LA85 strain, and the weight value of the mouse is stabilized; the glucose absorption and metabolism capability of diabetic mice is effectively improved, and continuous damage of pancreatic beta cell functions is retarded; the blood lipid level disorder state of the mouse with the type II diabetes mellitus is improved; the inflammation level of a mouse body with type II diabetes mellitus is reduced, and the immunity is improved; and a very good improvement and recovery effect is achieved on abundance and diversity reduction of intestinal flora of the type II diabetes mellitus mice.

This invention belongs to the technical field of pharmaceuticals, health foods, and medicines, specifically relating to Russula polysaccharide, its extraction method, and its application in anti-inflammatory, antioxidant, and / or hypoglycemic effects. This invention employs an ultrasound-assisted enzymatic hydrolysis method to extract Russula polysaccharide, thereby significantly improving extraction efficiency, reducing enzyme dosage, protecting the polysaccharide structure, and increasing yield and purity. Furthermore, experimental verification shows that it possesses good anti-inflammatory, antioxidant, and / or hypoglycemic effects, and when combined with Phyllanthus emblica polysaccharide, it synergistically enhances hypoglycemic performance, thus demonstrating significant practical application value.

Provided herein are pharmaceutical formulations comprising glucokinase activator, or a prodrug, or a pharmaceutically acceptable salt, an isotope labeled analogue, a crystalline form, a hydrate, a solvate, or a diastereomeric or enantiomeric form thereof and the use thereof for treating diseases; the pharmaceutical formulations are in the form of immediate-release formulations, extended-release formulations, or combination of immediate-release formulation and extended-release formulations. The pharmaceutical formulations achieved once-a-day therapy for some diseases, in particular, type II Diabetes Mellitus with obesity. The pharmaceutical formulations exhibit sustained 24 hours of glucose-lowering effects. The pharmaceutical formulations also achieved lower Cmax, extended T1 / 2 as well as maintained similar bioavailability and increased MRT compared with commercial Dorzagliatin tablet, enhanced the pharmacology effect of restoring the glucose stimulated GLP-1 secretion in diabetes with obesity.

This invention discloses a meglumine-luteolin complex, its preparation method, and its applications, belonging to the interdisciplinary field of microbiome and drug delivery. Using luteolin as the main material, this invention employs a dual inclusion technique with hydroxypropyl-β-cyclodextrin and meglumine to synergistically prepare a meglumine-luteolin complex with colon-targeted delivery capabilities. This invention significantly improves the delivery efficiency and drug loading of luteolin in the colon through the dual inclusion technique. The preparation process is simple, and it exhibits excellent hypoglycemic effects and colon-targeted release characteristics in the treatment of diabetes and its complications.

The invention discloses a preparation rich in polygonatum sibiricum polypeptide and application of the preparation in diabetes mellitus. The composition is prepared from rhizoma polygonati polypeptide, semeglutide, astaxanthin, an active agent and a ferroptosis mixture. Pharmacodynamic experiments show that in a diabetic mouse model, fasting blood glucose can be remarkably reduced, the serum insulin level can be increased, renal function indexes can be improved, and expression of NLRP3 inflammation pathway related proteins (NLRP3, Caspase-1 and IL-1beta) in pancreatic tissue can be remarkably inhibited. By integrating multiple mechanisms of blood glucose reduction, oxidation resistance, inflammation resistance, ferroptosis resistance and the like, multi-target collaborative intervention is realized, the pharmaceutical composition is remarkably superior to a single component in the aspects of blood glucose reduction, pancreas islet function protection and complication alleviation, and a new clinical strategy is provided for treatment of diabetes mellitus, especially type 1 diabetes mellitus.

The application discloses a quinoa hexapeptide with a blood sugar lowering effect and application thereof, and belongs to the technical field of bioactive peptides. The amino acid sequence of the quinoa hexapeptide PGSPGR is Pro-Gly-Ser-Pro-Gly-Arg. The quinoa hexapeptide PGSPGR has alpha-glucosidase inhibitory activity and can effectively reduce blood sugar level, and therefore, can be applied to preparation of medicines or food for lowering blood sugar. The application further provides a polypeptide containing the peptide segment PGSPGR and a quinoa peptide rich in the polypeptide, and the polypeptide and the quinoa peptide are applied to preparation of medicines or food for lowering blood sugar, thereby providing a new scheme and theoretical basis for treatment of diabetes, and having good market prospect and application potential.

The invention belongs to the technical field of natural medicines, and discloses an application method of a synsepalum dulcificum extract in treatment of diabetes mellitus, and the synsepalum dulcificum extract is a natural plant extract and has no obvious toxic or side effect. Compared with chemically synthesized drugs, the traditional Chinese medicine composition does not cause serious damage to important organs such as liver and kidney after long-term use, and the tolerance of patients is good. The hypoglycemic effect is achieved by increasing insulin sensitivity, adjusting activity of glucose metabolism related enzymes, protecting pancreatic beta cells and the like, and the metabolic condition of diabetic patients can be more comprehensively improved. The preparation process of the extract is relatively simple, low in cost and easy for large-scale production. Meanwhile, medicines or health-care products based on the extract have various dosage forms, and can be selected according to the requirements and preferences of patients.

The invention discloses a preparation method of a medicinal and edible plant composition with a synergistic hypoglycemic effect, and relates to the technical field of preparation of medicinal and edible health products. The method comprises the following steps: step a, crushing jerusalem artichoke, bitter gourd and Chinese waxgourd peel according to a mass ratio of 1: (0.5-2): (0.5-1.5) until the particle size is 0.2-0.5 mm, performing cold soaking at 4-10 DEG C for 48-72 hours, and performing filtering to obtain a water-soluble component filtrate; step b, adding cellulase (the enzyme activity is greater than or equal to 10000 U / g) which accounts for 0.1-0.3% of the mass of the raw materials into the residues in the step a; according to the method, multi-process combined extraction is carried out, specifically, heat-sensitive components such as momordica saponins are reserved through cold extraction (4-10 DEG C), fat-soluble components are extracted through supercritical extraction, cell membranes are damaged through high-temperature transduction to release cinnamyl aldehyde, the synanthrin decomposition rate reaches 75% through the enzymolysis technology, the quercetin conversion rate is larger than or equal to 90%, and the quercetin content is larger than or equal to 30% through the enzymolysis technology. According to the invention, four mechanisms, namely alpha-glycosidase inhibition, insulin sensitization, oxidation resistance and GLUT4 transport promotion, are used for synergistically reducing blood glucose, the blood glucose reducing effect is remarkable, the absorption rate of fat-soluble components is increased by 2 times by the nano-emulsion, and the in-vivo half-life period of the balsam pear saponin is prolonged to 6.5 hours by the lipidosome.

The invention discloses a synthesis method of a fullerene nano material with glycolipid metabolism regulation capability, and belongs to the technical field of material science and biomedical engineering. The fullerene and the metformin are combined through chemical bonds, the strong oxidation resistance of the fullerene and the hypoglycemic effect of the metformin are exerted at the same time, the synergistic treatment effect is formed, and the drug composition is superior to a single drug; active oxygen in cells can be efficiently removed, oxidative stress is effectively relieved, and the functions of pancreatic beta cells are protected; through structural modification, the problem of low bioavailability caused by hydrophobicity of fullerene and hydrophilicity of metformin is solved, and the solubility and absorption efficiency of the medicine are improved; in conclusion, through chemical combination of the fullerene and the metformin, a dual-mechanism synergistic effect of oxidation resistance and blood sugar reduction is achieved, the treatment effect is remarkably improved, meanwhile, good safety and biocompatibility are achieved, and important application value is achieved in the field of treatment of the type II diabetes mellitus.

The invention belongs to the technical field of traditional Chinese medicine, and relates to polygonum cuspidatum homogeneous polysaccharide and a preparation method and application thereof.The polygonum cuspidatum homogeneous polysaccharide is mainly composed of galacturonic acid, rhamnose, galactose, glucuronic acid, glucose, mannose, xylose and glucuronide amine according to the molar ratio of 41.967: 24.624: 17.951: 5.427: 4.59: 3.501: 1.236: 0.358, and the weight-average molecular weight of the polygonum cuspidatum homogeneous polysaccharide is 26.57 kDa. The polygonum cuspidatum homogeneous polysaccharide is fixed in component, high in yield, good in hypoglycemic effect and good in safety, and a basis is provided for development of innovative hypoglycemic drugs.